In drug delivery to cancer tissues, conjugation of biomarkers are recently introduced? But, biomarker may suffered some changes in the body? My questions are these: First, what are the biological factors that decrease the delivery potentials of biomarkers? Second, how to protect biomarkers conjugated to nanodrugs form these biological barriers?